Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levosulpiride + pantoprazole
- Development stage
- Unknown
- Lead developer
- Croise Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Krozole-L (levosulpiride + pantoprazole) is a fixed-dose combination capsule developed and marketed by Croise Pharma for the treatment of gastrointestinal disorders, particularly gastroesophageal reflux disease (GERD), functional dyspepsia, and acid reflux. The combination pairs pantoprazole, a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, with levosulpiride, a selective dopamine D2 receptor antagonist and moderate 5-HT4 receptor agonist that acts as a prokinetic agent to enhance gastrointestinal motility and accelerate gastric emptying. Together, these two active ingredients address both the acid hypersecretion and impaired motility that underlie refractory GERD and dyspepsia.
- Brand names
- Krozole-L
- Other names
- levosulpiride and pantoprazolepantoprazole + levosulpiridepantoprazole and levosulpiride
02
Targets
HTR4 (5-Hydroxytryptamine receptor 4)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)ATP4B (Potassium-transporting ATPase subunit beta)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on levosulpiride + pantoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levosulpiride + pantoprazole.